Comparative Study on Phytochemical Profiles, Antiproliferative, Antimicrobial and Antioxidant Activities of Adonis Species from Turkey

Karahan, Faruk; Avşar, Cumhur; Türkmen, Musa; Gezici, Sevgi; İlçım, Ahmet

doi:10.1007/s11094-022-02693-0

Cited by 5 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Newman and Cragg (2020) reported that from 1981 to 2019 there was 1881 new remedies, which were approved for medical application, and the 22.9% of them are of natural origin. Phytotherapy plays an important role in the treatment of cardiovascular ( Kirichenko et al, 2020 ; Archakova et al, 2022 ; Karahan et al, 2022 ), immune ( Babich et al, 2020 ; Ligacheva et al, 2022 ; Abdugafurova et al, 2024 ), cancer ( Medvedev et al, 2020 ; Kitaeva et al, 2022 ; Jia-Xing et al, 2023 ), and infectious diseases ( Gorlenko et al, 2020 ; Luzhanin et al, 2022 ; Zrig, 2022 ). According to the WHO, herbal medications are the main choice in many regions of the world ( Aware et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Insights into the stereoisomerism of dihydroquercetin: analytical and pharmacological aspects

Terekhov,

Savina,

Pankov

et al. 2024

Front. Chem.

View full text Add to dashboard Cite

Dihydroquercetin (DHQ) is a representative of flavonoids that is available on the market as a food supplement and registered as an active pharmaceutical ingredient. The structure of this compound is characterized by the presence of two chiral centers in positions 2 and 3 of the pyranone ring. Current regulatory documentation on DHQ lacks quantitative analysis of the stereoisomers of this flavanonol. This poses potential risks for consumers of DHQ-based dietary supplements and developers of new drugs. This review was conducted to systematize data on the pharmacology of DHQ stereoisomers and the possible methods of controlling them in promising chiral drugs. We found that relying on literature data of polarimetry for the identification of DHQ stereoisomers is currently impossible due to these heterogeneities. NMR spectroscopy allows to distinguishing between trans- and cis-DHQ using chemical shifts values. Only HPLC is currently characterized by sufficient enantioselectivity. Regarding pharmacology, the most active stereoisomer of DHQ should be identified, if the substituents in chiral centers both take part in binding with the biological target. The significant impact of stereochemical structure on the pharmacokinetics of DHQ isomers was reported. The question about these toxicity of these compounds remains open. The results of the conducted review of scientific literature indicate the necessity of revising the pharmacology of DHQ taking into account its stereoisomerism.

show abstract